Skip to main content

Table 1 Examples of drugs targeting tyrosine kinases receptors that are being tested in different clinical trials

From: Receptor tyrosine kinases and downstream pathways as druggable targets for cancer treatment: the current arsenal of inhibitors

MET Tivantinib Advanced/Recurrent Gastric Cancer II Completed NCT01152645
MET/EGFR/Topoisomerase Tivantinib + cetuximab + irinotecan Metastatic Colon Cancer I/II Completed NCT01075048
MET/EGFR Tivantinib + erlotinib NSCLC III Completed NCT01244191
MET/EGFR Tivantinib + erlotinib Locally Advanced or Metastatic NSCLC II Completed NCT01395758
MET/Thymidylate Synthase Tivantinib + FOLFOX Advanced Solid Tumors and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction or Stomach I Completed NCT01611857
MET Tivantinib Metastatic Breast Cancer II Completed NCT01575522
EGFR Erlotinib Bladder Cancer II Completed NCT00380029
EGFR Erlotinib Advanced Head and Neck Cancer II Terminated NCT00750555
EGFR Gefitinib Recurrent or Metastatic Esophageal or Gastroesophageal Junction Cancer II Completed NCT00268346
EGFR Gefitinib Advanced or Metastatic Thyroid Cancer II Completed NCT00095836
EGFR Afatinib Hormone-Refractory Prostate Cancer II Completed NCT01320280
EGFR Afatinib Breast Cancer II Completed NCT01325428
EGFR Afatinib Head and Neck Cancer III Terminated NCT01345669
EGFR Rociletinib or Erlotinib Metastatic NSCLC II Terminated NCT02186301
EGFR Lapatinib + Ciscplatin + Radiotherapy Head and Neck Cancer II Terminated NCT00387127
PDGFR/Microtubule Dasatinib + Ixabepilone Metastatic Breast Cancer I Completed NCT00924352
PDGFR/Microtubule Dasatinib + Docetaxel Metastatic Hormone-Refractory Prostate Cancer II Completed NCT00439270
PDGFR/EGFR Dasatinib + Erlotinib NSCLC II Completed NCT00826449
Multiple Receptor Tyrosine Kinases (PDGFR, c-KIT, VEGFRs) Sunitinib Pancreatic Neuroendocrine Tumors III Terminated NCT00428597
Multiple Receptor Tyrosine Kinases (PDGFR, c-KIT, VEGFRs) Sunitinib Esophageal Cancer II Completed NCT00702884
Multiple Receptor Tyrosine Kinases (PDGFR, c-KIT, VEGFRs)/Microtubule/EGFR Sunitinib + Docetaxel + Trastuzumab Advanced Breast Cancer I Completed NCT00372424
ALK Ceritinib Tumors Characterized by Genetic Abnormalities in ALK I Completed NCT01283516
MET and VEGFR Cabozantinib Prostate Cancer II Completed NCT01834651
VEGFR/Microtubule Bevacizumab + Paclitaxel Metastatic Breast Cancer (HER-2 negative) II Active NCT01663727
  1. FOLFOX is a chemoterapy regimen (folinic acid, fluorouracil, oxaliplatin)
  2. NSCLC Non-small Cell Lung Cancer, ALK Anaplastic Lymphoma Kinase